Business
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV:...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology CongressToronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the 2026 European Association of Urology Congress (\"EAU26\").The EAU has accepted Theralase®'s abstract titled, \"Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ\" for presentation at EAU26 to be held in London, United Kingdom, from March 13th to 16th, 2026.The interim clinical data from Theralase®'s international, multicenter Phase II Bacillus Calmette-Guérin (\"BCG\")-Unresponsive Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Carcinoma In-Situ (\"CIS\") study (\"Study II\") will be presented by principal investigator Dr. Girish Kulkarni in an oral presentation. Enrollment has been completed in Study II and Theralase® expects to commence submission of the clinical data in a rolling review to Health Canada and the FDA in 3Q2026. Pending regulatory approval, expected in 2027, this innovative technology represents an opportunity for a significant advancement in bladder cancer therapy, providing a safe and effective treatment for patients, who have exhausted their standard of care therapeutic options and are facing radical cystectomy (bladder removal).The interim clinical data supports potential safety and efficacy of the treatment with 2 out of 3 patients obtaining a complete response and 2 out of 5 patients maintaining that complete response for 15 months or more. In post study analysis, 1 out of 5 patients have demonstrated a duration of response of 3 years or greater with a single treatment.These interim preliminary findings are encouraging in support of the use of light-activated Ruvidar® by the international urology community to safely and effectively treat patients afflicted with BCG-Unresponsive NMIBC CIS, helping to revolutionize the treatment landscape for bla...